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Schizophrenia and eating disorders (EDs) are complex traits with considerable somatic and 
psychiatric morbidity. Despite distinct diagnostic criteria and few symptoms in common, 
significant genetic correlations between schizophrenia and anorexia nervosa (AN) have been 
illustrated in several recent genomic studies. However, the genetic association between 
schizophrenia and EDs other than AN is still unknown, and whether these disorders have 
common familial risk is unclear. This thesis extends the understanding of the underlying 
shared etiological pathway between schizophrenia and EDs, investigates its influences on 
clinical outcomes of EDs, and explores the broad impact of schizophrenia genetic risk on a 
wide range of medical conditions. 
In Study I, we applied a family design to estimate the familial co-occurrence and co-
aggregation of schizophrenia and EDs in population-based cohorts from Sweden and 
Denmark. Significantly increased risk of schizophrenia was found in individuals with EDs (6-
7 times the risk) as well as their relatives (highest in first-degree relatives and diminished 
with decreasing genetic relatedness) compared with individuals without EDs and their 
relatives, indicating that familial liabilities including common genetic and/or shared 
environmental factors contribute to the associations between schizophrenia and EDs. 
In Study II, we investigated the effect of a family history of schizophrenia on clinical 
outcomes including ED clinical features, psychiatric comorbidities, and somatic and mental 
health burden in individuals with EDs from a population-based ED case cohort identified 
from Swedish national registers. Family history of schizophrenia was associated with 
increased somatic and mental health burden, but less severe ED-related symptoms in 
individuals with AN. It was also associated with increased risk of psychiatric comorbidities, 
cumulative health burden, and suicide attempts in individuals with other eating disorders 
(OED). These findings suggest that family history of schizophrenia might be a potential 
factor for clinically meaningful ED case stratification. 
In Study III, we evaluated the impact of schizophrenia genetic predisposition conferred by 
polygenic risk scores (PRS) on clinical outcomes of EDs in cases from two ED studies: the 
Anorexia Nervosa Genetics Initiative-Sweden (ANGI-SE) and the Binge Eating Genetics 
Initiative-Sweden (BEGIN-SE). Schizophrenia PRS was positively associated with comorbid 
major depressive disorders (MDD), but negatively associated with clinical impairment 
assessment (CIA) scores in ANGI cases. BEGIN cases who had higher schizophrenia PRS 
had increased risk of MDD and substance abuse disorders (SUD), greater cumulative health 
burden, and higher ED pathology scores. These findings suggest a different pattern of 
influence of schizophrenia PRS for AN compared with OED with reference to clinical 
outcomes. 
In Study IV, we explored the pleiotropic effect of schizophrenia PRS in over 400,000 
individuals without schizophrenia from the UK Biobank. We found poorer self-reported 
overall health condition, more hospital inpatient contacts, more total diseases diagnosed in 
individuals with higher schizophrenia PRS. Specifically, we found schizophrenia PRS were 
statistically significantly associated with multiple illnesses including mental disorders, 
musculoskeletal diseases (negatively associated), respiratory diseases, digestive diseases, 
pituitary hyperfunction, etc., demonstrating that genetic risk for schizophrenia also impacts 
risk for numerous other health conditions.  
In conclusion, this thesis enhances the understanding of the convergent etiology among 
schizophrenia, EDs, and other medical conditions; highlights the influences of schizophrenia 
genetic predisposition on clinical outcomes of EDs; and demonstrates the broad impact of 
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Comorbidity is the presence of two or more illnesses or conditions occurring in an individual 
at the same time or sequentially. Comorbidity is typically linked to poorer overall health, 
more complicated clinical treatment, and high healthcare expenses1. It is clinically 
meaningful to understand whether underlying shared etiological pathways exists between 
comorbid conditions, and if so, how etiological sharing influences or informs clinical care. In 
this thesis, I mainly focused on two specific disorders, schizophrenia and eating disorders 
(EDs), to further explore these questions.  
Schizophrenia is a severe mental disorder characterized by disordered thoughts, perceptions, 
and behavior, affecting about 20 million people worldwide2, 3. Over the past 30 years, the 
percentages of total Disability-Adjusted Life Years (DALYs) caused by schizophrenia have 
risen continuously4. EDs, including anorexia nervosa (AN), bulimia nervosa (BN), binge-
eating disorder (BED), and eating disorders not otherwise specified (EDNOS), are also 
serious illnesses, associated with high and increasing DALYs4. Somatic and psychiatric 
comorbidity as well as elevated mortality are common in individuals with schizophrenia and 
all EDs5-8. 
Despite schizophrenia and EDs sharing few symptoms, significant positive genetic 
correlations between schizophrenia and AN have been reported previously9-11. This 
observation merits additional investigation into the etiological and clinical relationships 
between these disorders. Moreover, the understanding of the genetics of EDs other than AN 
(i.e., bulimia nervosa [BN], binge-eating disorder [BED], etc.) is still limited, as are their 
genetic correlation with schizophrenia. Whether these other eating disorders (OED) share 
familial risk with schizophrenia is also unknown. Furthermore, it is worthwhile to understand 
the impact of shared factors between schizophrenia and EDs on the clinical outcomes for 
EDs. Investigating these questions can provide new insights into the different manifestations 
of EDs and shed light on the convergent etiology of schizophrenia and EDs.  
In addition, people with schizophrenia have increased risk for additional psychiatric and 
somatic health problems12, 13. Quantifying the risk conveyed by shared genetic factors is 
essential to better understand the underlying mechanisms in service of more personalized 
clinical care. 
This thesis comprises four studies that examine the association between schizophrenia and 
EDs including the underlying shared factors (especially genetic factors) and its influence on 
the clinical presentations, as well as the broad impact of schizophrenia genetic risk on other 





2 BACKGROUND  
2.1 SCHIZOPHRENIA 
Schizophrenia is a severe mental disorder characterized by an array of symptoms including 
positive symptoms (delusions, hallucinations, disorganized thinking, etc.), negative 
symptoms (diminished emotional expression, loss of motivation and initiative, paucity of 
speech, etc.), and cognitive impairment (impaired reasoning, deficit in social cognition, etc.)3. 
Schizoaffective disorder is a chronic mental disorder characterized by a combination of the 
symptoms of schizophrenia and mood disorder symptoms (depression, mania, etc.)3. Studies 
in this thesis focus on both schizophrenia and schizoaffective disorder. 
2.1.1 Diagnostic criteria and epidemiology 
Although the search for schizophrenia biomarkers continues, clinical review of signs and 
symptoms remains the only reliable way to establish a diagnosis of schizophrenia in current 
clinical practice. The most widely used explicit diagnostic systems for psychiatric disorders 
are: the International Classification of Disease (ICD), and the Diagnostic and Statistical 
Manual of Mental Disorders (DSM). The latest versions for each are the eleventh edition of 
ICD (ICD-11) released in 2018, and the fifth edition of the DSM (DSM-5) released in 
201314, 15. In the Swedish diagnostic system, clinicians typically diagnose patients using 
DSM criteria, and relevant ICD codes (ICD-8 since 1969, ICD-9 since 1987, and ICD-10 
since 1997) are recorded in the Swedish National Patient Register.  
The lifetime prevalence of schizophrenia is estimated to be 0.4%, with population-specific 
estimates ranging from 0.1% to 2.3%16, 17. Given that the diagnostic criteria for 
schizoaffective disorder have been altered frequently since its inclusion in the DSM and 
ICD18, few large-scale studies document its epidemiology, prevalence, or incidence. 
However, the lifetime prevalence of schizoaffective disorder has been reported to be around 
0.3% in Finland and Denmark19, 20. There are no significant differences in schizophrenia 
prevalence between males (0.37%) and females (0.34%)16, while the incidence rates 
differed significantly with a median rate ratio for male to female of 1.421. Moreover, 
schizoaffective disorder occurs slightly more frequently in women than in men22.  
The typical age of onset for schizophrenia is in late adolescence or early adulthood23, 
whereas schizoaffective disorder has a broad age of onset in adults. Men have an earlier age 
of onset for schizophrenia, with a single peak between 21 and 25 years old, compared with 
women who have two peak ages of onset, one between 25 and 30 and the other after 45 




Genetic factors are clearly implicated schizophrenia etiology. Family studies show that risk 
for schizophrenia in individuals who have relatives with schizophrenia increases with 
degree of genetic relatedness25, 26. Specifically, the risk for schizophrenia in individuals 
who have second degree relatives (grandparent, half sibling, aunt, or uncle) with 
schizophrenia is 3 to 4 times greater than in the general population. Individuals with first 
degree relatives (parent, offspring, or full sibling) who have schizophrenia have 8 to 10 
times increased risk for schizophrenia than the general population26. The risk for dizygotic 
twins is 17% whereas the risk for monozygotic twins is 48% when their co-twin is 
affected25, 26. The genetic contribution to risk for schizophrenia is then quantified by 
heritability estimated from twin and family studies—64%-81% of schizophrenia phenotypic 
variance can be explained by additive genetic variance between individuals27-29.  
Genome-wide association studies (GWAS) enable the detection of specific genetic risk 
factors by identifying single nucleotide polymorphism (SNP) loci with differing allele 
frequencies between people with and without schizophrenia. Over 280 common genetic 
variants have been associated with increased risk for schizophrenia30-32. Individually, each 
has a small effect size, indicating that numerous genes in combination contribute to 
schizophrenia liability.  
Polygenic risk scores (PRS) are continuous individualized indices which were developed to 
quantify the genetic risk for certain traits by summing risk from multiple genetic variants 
throughout the genome weighted by the strength of their associations as asses sed by 
GWAS33-35 (further explanation about PRS can be found in 4.3.2). The association between 
schizophrenia PRS and schizophrenia status is quite strong30, 36. As GWAS sample size 
increases, PRS become more robust, and current schizophrenia PRS explains 22.1% of 
variation in liability to schizophrenia30, 32. Nonetheless, PRS provide a tool to index genetic 
risk and offer a valuable measure for the exploration of gene-environment interactions and 
cross-disorder or comorbidity investigations.  
In addition to common variants included in GWAS studies, rare genetic variants such as the 
large deleted or duplicated segments of DNA termed copy number variants (CNVs) also 
play a role in the etiology of schizophrenia37. More than ten CNVs on several chromosomes 
were found to be associated with significant risk of schizophrenia (odds ratios 2-60)38-41. 
Moreover, a joint effect of rare CNVs and PRS has been found to contribute to 
schizophrenia risk42. Rare single variants examined through exome sequencing (e.g., rare 
loss-of-function variants in SETD1A) have also demonstrated significant contribution to 
risk for schizophrenia43-45.  
 
 5 
2.1.3 Adverse consequences 
Schizophrenia is associated with impaired ability to function46. Small delays in receiving 
treatment can affect the ability to function independently, and delays of more than a year 
significantly worsen prognosis47.  
Individuals with schizophrenia are also at increased risk for additional health problems, 
including both psychiatric disorders and somatic diseases. Abundant evidence documents 
increased prevalence of anxiety, depression, obsessive- compulsive disorder (OCD), post-
traumatic stress disorder (PTSD), and substance use disorders (SUD) in patients with 
schizophrenia compared with the general population13, 48-50 (Figure 2.1). 
 
Figure 2.1. Prevalence of common somatic and psychiatric comorbidities in individuals 
with schizophrenia and in the general population.  
Data obtained from literature13, 49, 51-65.  
SUD is the most common comorbidity among schizophrenia patients, which can involve a 
variety of substances, including alcohol, tobacco, illicit drugs, and prescription 
medications14, 66. Psychiatric comorbidities such as anxiety, depression, and OCD, can 
exacerbate the symptoms of schizophrenia14, 66. Moreover, based on a Swedish national 
cohort study, schizophrenia patients have significantly increased risk for stroke, diabetes 
mellitus (all types), influenza or pneumonia, and chronic obstructive pulmonary disease 











































































































Schizophrenia population General population
 
6 
disease with the prevalence significantly higher in schizophrenia patients, 12.5% of women 
and 11.0% of men, compared to 5.1% of women and 6.4% of men in the general 
population67. Notably, the increased risk of diabetes in patients with schizophrenia may 
result from antipsychotic medication use which often causes weight gain68. Autoimmune 
disorders, metabolic disturbances, and dementia are also more common in patients with 
schizophrenia compared to the general population52, 58, 69 (Figure 2.1).  
Furthermore, several major causes of death were found to be elevated in schizophrenia with 
suicide demonstrating the highest standardized mortality ratio of 12.921. Individuals with 
schizophrenia have lower fecundity with a fertility ratio of 0.23 for men and 0.47 for 
women compared to the general population70.  
2.2 EATING DISORDERS 
Eating disorders (EDs) are serious illnesses characterized by disturbance of basic functions 
of eating and recognized diagnoses include anorexia nervosa (AN), bulimia nervosa (BN), 
binge-eating disorder (BED), and other specified feeding and eating disorders (OSFED) in 
DSM-514. Studies in this work focus on AN and all other types of eating disorders – OED 
(defined below).  
2.2.1 Diagnostic criteria and epidemiology 
2.2.1.1 Anorexia nervosa 
AN is defined as restriction of energy intake leading to weight loss or a failure to gain 
weight resulting in a significantly low body weight, intense fear of gaining weight or 
becoming fat even though at a significantly low weight, and disturbed body weight or shape 
perception14. AN has two subtypes: a restricting type marked by restricting energy intake 
and a binge-eating/purging type where recurrent episodes of binge eating and/or purging 
are common3, 14. Patients with restrictive behaviors and fear of weight gain who do not meet 
the low weight criteria are given a diagnosis of atypical AN71. In the Swedish diagnostic 
system, AN is detectable as an independent psychiatric disorder since 1987, using the 
Swedish version of the ICD-9.  
The lifetime prevalence of AN ranges from 0.1-0.3% for males in samples from the US and 
Sweden and is reported by less than 1% to 4% of women in Europe from community-based 
studies8, 72, 73. Onset is commonly around puberty, but it can affect young children and older 
adults3, 23. While it is generally observed in clinics that males present with AN less 
frequently than females, the prevalence in males is higher than previously thought—with 
female to male ratios ranging from 1:1 to 10:114, 74, 75. A smaller female-to-male ratio is 




2.2.1.2 Other eating disorders 
Since ICD-9, AN (307B) has been coded separately and thus is uniquely identifiable. EDs 
other than AN are not uniquely distinguishable by diagnostic codes and are therefore 
categorized as “other eating disorders” (OED) in these studies.  
OED as defined here includes BN, BED, and eating disorders not otherwise specified 
(EDNOS). BN is characterized by recurrent episodes of binge eating when individuals 
consume a great quantity of food in a short period of time with a sense of lack of control 
over eating (at least once a week for three months). In addition, recurrent inappropriate 
compensatory behaviors are present to avoid weight gain 71. People who meet all of the 
diagnostic criteria but with lower frequency of binge-eating and purging behaviors fulfil the 
diagnosis of atypical BN. BED is marked by recurrent episodes of binge eating but without 
the recurrent inappropriate compensatory behaviors14. However, BED was subsumed under 
EDNOS in DSM-IV, and not defined as an independent diagnosis until DSM-514. 
Individuals who have EDs but do not meet the criteria above are given a diagnosis of 
OSFED since the release of DSM-5 (2013)14. Previously, they were given a diagnosis of 
EDNOS71.  
BN usually has its onset in late adolescence or early adulthood, while BED typically starts 
in early adulthood72. The lifetime prevalence of BN is estimated to be 0.5-2.8% in women 
and 0.1- 0.5% in men72, 78. BED is the most common ED diagnosis with a lifetime 
prevalence of 1.9-3.5% in females and 0.3-2.0% in males72, 78. BN is more common in 
females than males, and the sex ratio is 10:1 based on clinical samples14. However, the sex 
ratio is less skewed for BED than other ED diagnoses with a female to male ratio of 2:172.  
2.2.2 Genetics 
Genetic liability to EDs was first reported in familial aggregation studies. Individuals with 
first-degree female relatives with AN have 11 times higher risk of AN compared to those 
whose first-degree female relatives do not have AN79. First-degree relatives of probands 
with BN have a 4.4 times higher rate of BN than relatives of the comparison probands 
without BN79. Familial aggregation of BED independent of obesity has also been found in 
US samples80. Furthermore, based on twin studies from various samples, EDs are highly 
heritable conditions with heritability of 58%-76% for AN, 54%-83% for BN, and 41%-57% 
for BED81-83.  
GWAS of AN has recently identified several risk loci, showing significant genetic 
correlations with not only psychiatric disorders but also metabolic and anthropometric 
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traits84, 85. One GWAS has been conducted for BN spectrum with self-report data. However, 
no variant met the genome-wide significance threshold86. No GWAS of BN or BED traits 
has been conducted to date. Although GWAS on EDs are limited, a recent study which 
associated PRSs for 296 different diseases and traits with ED subtypes detected clear 
differences between binge-type EDs and AN in terms of associations with several PRSs 
(including opposite directions of associations with PRSs related to body mass regulation) 
suggesting genomic differences among AN, BN, and BED87. Investigations of shared and 
unique genetic factors across different ED subtypes are needed. 
2.2.3 Clinical outcomes 
It is not uncommon for individuals to present with different ED diagnoses across the course 
of their illness88-90. However, according to a study within the Swedish population, the 
transition pattern usually occurs from or to EDNOS, whereas transition across threshold 
diagnoses of AN, BN, and BED is less common90. Remarkably, diagnostic crossover 
between AN and BN reduces the likelihood of remission and indicates poor prognosis90, 91. 
Psychiatric comorbidities in individuals with EDs are common. The majority (55-97%) of 
individuals diagnosed with an ED also receive a diagnosis of at least one other psychiatric 
diagnosis, including mood disorders, anxiety disorders (particularly OCD and social 
anxiety disorder), PTSD, and/or SUD92-96. However, the patterns of comorbidities differ 
across different types of EDs. For example, BN is associated with greater risk of SUD and 
attention-deficit hyperactivity disorder (ADHD) than AN72, 73. Moreover, individuals with 
BN who have comorbid borderline personality disorder have poorer prognosis than those 
without borderline personality disorder when both groups are treated with psychotherapy 
and pharmacotherapy97, 98.  
EDs are also associated with multiple physical complications and dysfunction. AN is often 
accompanied by various medical complications including constipation, gastroparesis, 
osteoporosis, anemia, brain atrophy, electrolyte abnormalities, hypotension, cardiac 
arrhythmias, abnormal thyroid functioning, and amenorrhea due to weight loss and 
malnutrition99, 100. BN is associated with dangerous electrolyte abnormalities, dehydration, 
oral mucositis, cheilitis, erosion of dental enamel, etc. due to the mode and frequency of 
purging99, 100. Although BED has become a new category only recently (in DSM-5), it has 
been found to be associated with type 2 diabetes and metabolic syndrome independent of 
obesity101.  
EDs are one of the 12 leading causes of hospitalization costs due to mental health in 
Australia96. Hospitalization for complications related to EDs are found to be increasing due 
to both increases in first admissions as well as readmissions96. Moreover, AN has the 
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second highest mortality rate of any mental disorder102. The mortality rate is similar in BN 
and EDNOS, which is lower than AN but still higher than the general population5. 
Furthermore, the risk of suicide attempts is elevated not only in individuals with EDs but 
also their full siblings73.  
It is essential to clarify the factors that influence clinical outcomes of EDs which might 
assist identifying specific risk groups for targeted interventions.  
2.3 CROSS-TRAIT ASSOCIATIONS AND PLEIOTROPY 
2.3.1 Association between schizophrenia and eating disorders 
Associations between schizophrenia and symptoms of EDs have been explored in a few 
epidemiological investigations. Results from a small case-control study show associations 
between eating disturbances including pica, faddiness, and food refusal in childhood and 
schizophrenia in adulthood103. Associations between psychotic experiences during early 
adolescence and increased risk for disordered eating behaviors (e.g., binge eating, purging, 
fasting) in late adolescence were also observed from a UK birth cohort104. Moreover, co-
occurrence of diagnosed schizophrenia and EDs has also been investigated in some small 
clinical samples105-107. Furthermore, the National Survey of American Life (NSAL) 
revealed an association between self-reported first-degree family history of schizophrenia 
and the increased lifetime risk for BN108. However, since these results were primarily based 
on small clinical samples or self-reported data, it is essential to examine whether the co-
occurrence and familial co-aggregation of clinically diagnosed EDs and schizophrenia 
present at the population level.  
Despite schizophrenia and EDs sharing few clinical symptoms, significant positive SNP-
based genetic correlations between schizophrenia and AN have been reported in previous 
studies (rg= 0.19-0.29)11, 84, 85. However, the genetic association between schizophrenia and 
EDs other than AN is lacking, and whether these disorders have common familial risk 
remains to be investigated. The impact of a family history of schizophrenia (indicating high 
genetic risk) on clinical outcomes for EDs is still unknown. Investigating these questions 
can provide new insights into the different manifestations of EDs and shed light on the 
convergent etiology of schizophrenia and EDs.  
2.3.2 Pleiotropic mechanisms underlying cross-trait associations  
In addition to the genetic correlation between schizophrenia and EDs, recent GWAS and 
genomic analysis results also pointed out the overlap among psychiatric disorders (e.g., 
strong positive genetic correlations between schizophrenia and bipolar disorder, AN and 
OCD, MDD and autism spectrum disorder [ASD], etc.), as well as between schizophrenia 
 
10 
and numerous other illnesses including anxiety, SUD, personality disorders, urinary 
syndromes, and malaise and fatigue, etc. 36, 109-112. These findings suggest a role for 
pleiotropic effects underlying complex traits.  
Pleiotropy is defined as a genetic factor including a gene, a genetic variant, or a 
combination of genetic variants that affects more than one trait113. It includes biological 
pleiotropy, where the genetic factor affects both traits directly; mediated pleiotropy, where 
the genetic factor affects one trait through its impact on the other trait; and spurious 
pleiotropy, where a false pleiotropy is suggested due to phenotypic misclassification, 
ascertainment bias, etc.113, 114. Distinguishing between biological pleiotropy and mediated 
pleiotropy is crucial as this affects both interpretation and implementation in clinical 
practice. 
PRS is an aggregate measure of genetic variation that can be leveraged to assess whether 
pleiotropy exists between traits without pointing to any particular variant or region of the 
genome113. Recent studies have reported the pleiotropic effect of schizophrenia PRS on 
multiple medical conditions in the US patient population36, 110. The understanding of the 
pleiotropy of schizophrenia PRS could be advanced via assessment in a much larger 
population with longer follow-up. Restricting analyses to individuals without schizophrenia 
would also help to distinguish between biological pleiotropy as opposed to mediated 
pleiotropy. In the former, schizophrenia PRS can elevate risk for other conditions in the 
absence of schizophrenia, while the latter increases risk for these conditions as a result of 





The overall aim of this thesis work was to increase the understanding of the etiology of 
schizophrenia and EDs as well as the effect of schizophrenia genetic risk on ED clinical 
presentations and other medical conditions. 
The specific aims were: 
Study I. To explore the familial relationships between schizophrenia and EDs. 
Study II. To examine the association between family history of schizophrenia and clinical 
outcomes in individuals with EDs. 
Study III. To evaluate the impact of schizophrenia genetic risk on clinical presentations of 
EDs. 
Study IV. To investigate the influence of schizophrenia genetic risk on various health 





4 MATERIALS AND METHODS 
4.1 DATA SOURCES 
4.1.1 Swedish and Danish national registers 
Nordic countries have a long tradition in collecting and registering population statistics. 
Sweden and Denmark have nationwide registers with high quality data and similar structure, 
as well as personal identification numbers that allow registers to be linked115. In this thesis, I 
took advantage of multiple registers in Sweden and Denmark to identify diagnoses and the 
demographic characteristics through linking them. 
The follow-up period of each Swedish and Danish national register used in this thesis is 
shown in Figure 4.1. 
Figure 4.1 Follow-up period of the Swedish and Danish registers.  
Data obtained from literature116-124.  
A brief description of the Swedish and Danish national registers used in this thesis is 
presented in Table 4.1.1. 
Table 4.1.1 Swedish and Danish registers included in this thesis.  
Country Register Selected information used in this thesis Study 
Sweden TPR Sex, date and country of birth  I, II 




1930 1940 1950 1960 1970 1980 1990 2000 2010
National Patient Register (NPR) 
Multi-Generation Register (MGR) 
Swedish National Quality Register for Eating Disorders (Riksät) 
Cause of Death Register (CDR) 
Migration Register
Total population Register (TPR) 





1930 1940 1950 1960 1970 1980 1990 2000 2010
1875
National Patient Register (NPR) 
Medical Birth Register  (MBR) 
Psychiatric Central Research Register (PCRR) 
Causes of Death Register (CDR) 
Civil Registration System (CRS) 
1977 1994
ICD-8 ICD-10
Medical Birth Register (MBR)
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MGR Linkage between individuals and their biological 
and adoptive parents 
I, II 
NPR Discharge date, primary and secondary diagnoses 
on inpatient and outpatient admissions assigned by 
the attending physician according to the ICD 
system 
I, II, III 
RIKSÄT Date and ED diagnoses (according to DSM IV-
TR), BMI, GAF score, EDE-Q subscale and global 
score, CIA score at first registration and follow-up 
whenever available  
I, II 
Stepwise Date and ED diagnoses (according to DSM IV-
TR), BMI, GAF score, EDE-Q subscale and global 
score, CIA score at first registration and follow-up 
whenever available 
I, II 
CDR Date and causes of death (coded according to the 
ICD system) 
I, II, III 
Migration Register 
(based on TPR) 
Date of immigration and emigration I, II 
Denmark CRS Sex, birth year, linkage between individuals and 
their parents, places of residence, and vital status 
I 
NPR Date and diagnostic records on inpatient and 
outpatient admissions to public hospitals 
I 
PCRR Date and diagnostic records of all admissions to 
psychiatric inpatient facilities based on ICD system 
I 
MBR Congenital malformation information I 
CDR Date and causes of death (coded according to the 
ICD system) 
I 
Abbreviations: ED, eating disorder; BMI, body mass index; GAF, Global Assessment of Functioning; EDE-Q, Eating 




4.1.2 The Anorexia Nervosa Genetics Initiative-Sweden (ANGI-SE) 
The Anorexia Nervosa Genetics Initiative-Sweden (ANGI-SE) is a large-scale, case-control 
study that collected phenotypic data and blood samples for genotyping in individuals 
primarily diagnosed with AN with a linkage to Swedish National Registers125. Cases were 
recruited from multiple sources (including the Swedish National Quality Register for Eating 
Disorders (Riksät), Stockholm Centre for Eating Disorders (SCÄ), community outreach, and 
LifeGene126 participants) and identified by meeting DSM-IV-based case criteria for AN from 
the ED100K-v1 questionnaire responses or with a clinical AN diagnosis according to DSM 
IV-TR125. Population-based controls without a lifetime history of an ED were matched to 
cases from Riksät on age and sex by Statistics Sweden. Additional control samples were 
identified from LifeGene if they had screened negative for any ED history. All participants 
included in this study have completed the consent form. ANGI-SE includes 4118 cases and 
4035 controls, recruited between February 2013 and October 2016. The data from ANGI-SE 
cases are used in Study III. 
4.1.3 The Binge Eating Genetics Initiative-Sweden (BEGIN-SE) 
The Binge Eating Genetics Initiative-Sweden (BEGIN-SE) is an on-going large-scale case-
control study with genetic and phenotypic data in individuals with primary diagnoses of BN 
and BED (but also other EDs). Cases were recruited from the Swedish National Quality 
Register for Eating Disorders (Riksät) based on a structured diagnostic interview performed 
by a trained clinician or via algorithm based on responses from the ED100K-v2 questionnaire 
according to DSM-5. Age- and sex-matched controls without lifetime history or family 
history of an ED were recruited with help from a professional company from a population 
sample. The general exclusion criteria for participation in the BEGIN-SE study are: having 
any chronic inflammatory bowel disease (i.e., Crohn’s disease or ulcerative colitis), coeliac 
disease, having had a weight control operation (i.e. gastric bypass operation, gastric sleeve 
operation, adjustable gastric band operation), being pregnant or currently breastfeeding, 
undergoing a hormonal replacement therapy for a sex change operation, or under current 
antibiotic or probiotic treatment. All participants included in this study have completed the 
consent form. BEGIN-SE (freeze 1) includes 760 cases and 1240 controls, recruited between 
December 2017 and May 2020. The data from BEGIN-SE cases (freeze 1) are used in Study 
III. 
4.1.4 UK Biobank 
The UK Biobank is a large-scale biomedical research resource with approximately 500,000 
individuals aged 39 to 73 years recruited from England, Wales, and Scotland between 2006 
and 2010 with deep phenotyping and genomic data127. The linkage to the health-related 
records contains primary care, hospital in-patient records, cancer register data, and death 
records. Data from the UK Biobank are used Study IV. 
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4.2 MAIN MEASURES 
Data from multiple sources were retrieved to measure schizophrenia, EDs, other psychiatric 
conditions, cumulative somatic and mental health burden, and specific somatic and 
psychiatric illnesses. The definitions are described below. 
4.2.1 Schizophrenia 
Schizophrenia was defined as ≥2 inpatient or outpatient treatment contacts for schizophrenia 
or schizoaffective disorders from the NPR and CDR in Sweden, or ≥2 records of 
schizophrenia-related ICD codes from the PCRR, NPR, and CDR in Denmark. Relevant ICD 
codes are provided in Table 4.2. 
4.2.2 Eating disorders 
EDs were identified and classified with AN or OED based on relevant diagnoses from the 
NPR and ED quality registers (Riksät and Stepwise) in Sweden, or from the Danish NPR, 
PCRR, and CDR.  
AN included diagnoses of AN or atypical AN. OED was defined as EDs other than AN, i.e., 
having a diagnosis of any ED that was not AN. Relevant ICD codes and DSM criteria were 
provided in Table 4.2.  
4.2.3 Clinical features of eating disorders  
Clinical features of EDs included in this thesis were age at first ED diagnosis/symptom, the 
lowest illness-associated Body Mass Index (BMI), Eating Disorder Examination 
Questionnaire (EDE-Q) scores, Global Assessment of Functioning (GAF) scores, Clinical 
Impairment Assessment (CIA) scores, and hospital utilization related to ED. 
Age at first ED diagnosis/symptom was defined by the earliest age of first ED record in the 
Swedish NPR, or ED quality registers, or self-reported youngest age of any ED symptom, as 
available.  
Illness-associated BMI [weight (kg) / height (m2)] was obtained either from records of ED 
quality registers (Riksät and Stepwise) (Study II) or calculated based on self-reported height 
and weight in ANGI-SE and BEGIN-SE studies (Study III). The lowest illness-associated 
BMI was included in the analysis in Studies II and III. 
The EDE-Q is a self-report questionnaire which assesses current (in the past 28 days) ED 
symptoms and behaviors. It contains four subscales (Restraint, Eating concern, Shape 
concern, and Weight concern) and one global score. EDE-Q subscale and global scores were 
obtained from Swedish ED quality registers (Riksät and Stepwise) where the highest scores 
in records for each individual were used in the analysis in Study II. EDE-Q subscale and 
global scores obtained at the recruitment of BEGIN-SE study were used in Study III. 
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The GAF scale is used to assess how much the mental illness symptoms affect the person’s 
everyday life. The lowest GAF scores for each individual in records from Swedish ED 
quality registers (Riksät and Stepwise) were used in Study II.  
The CIA is a 16-item questionnaire which measures the severity of secondary psychosocial 
impairment due to ED features in the past 28 days. CIA scores obtained at the recruitment of 
ANGI-SE study participants were used in Study III. 
Hospital utilization related to ED was defined by total number of hospital contacts related to 
ED and total inpatient days related to ED obtained from the Swedish NPR. 
4.2.4 Other psychiatric comorbidities 
In Studies II and III, we identified diagnoses of psychiatric comorbidities with ED including 
MDD, OCD, anxiety disorder, ASD, ADHD, SUD from Swedish NPR and CDR. The ICD 
codes for each psychiatric disorder are presented in Table 4.2. 
4.2.5 Cumulative somatic and mental health burden 
Cumulative somatic and mental health burden was indexed by the total number of diagnoses, 
total number of all unique diagnoses/phecodes (see explanation in 4.2.6), total number of 
recorded suicide attempts, and total inpatient duration from the Swedish NPR for Studies II 
and III, and from the UK Biobank for Study IV, as available. The ICD codes for suicide 
attempts are presented in Table 4.2. 
4.2.6 Phecodes 
The phecode system was developed with the help of clinical experts in disparate domains 
combining one or more related ICD codes into distinct diseases or traits128, 129. Records from 
primary care data (Read code), hospital inpatient data (ICD-9 and ICD-10 codes), cancer 
register records (ICD-9 and ICD-10 codes), death register records (ICD-10 codes), and self-
reported medical condition codes from the UK Biobank were mapped into ICD-10 codes. 
These harmonized ICD-10 codes were then mapped with the phecode system for analyses in 
Study IV.  
4.2.7 Genetic measures 
ANGI-SE: 8,153 subjects had been genotyped on Infinium Global Screening Array including 
688,032 variants. 
BEGIN-SE: 1,469 subjects had been genotyped on Global Screening Array Multiple Disease 
(GSA-MD) including 730,059 variants. 
UK Biobank: 502,664 subjects had been genotyped on an Affymetrix chip including 800,000 
variants which had been imputed to millions of variants using the Haplotype Reference 
Consortium data, the merged UK10K and 1000 Genomes phase 3 as reference panels127. 
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GWAS summary statistics (from the Psychiatric Genomics Consortium-PGC) for 





Table 4.2 Summary of diagnostic criteria for psychiatric disorder measures in this thesis.  
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300.3 300D F42.0, F42.1, 
F42.2, F42.8, 
F42.9 













- II, III 
ASD Swedish 
NPR, CDR 
- 299A F84.0, F84.1, 
F84.5 
- II, III 
ADHD Swedish 
NPR, CDR 
- 314 F90.0, F90.1, 
F90.8, F90.9 
- II, III 
SUD Swedish 
NPR, CDR 



















Abbreviations: NPR, The National Patient Register; CDR, The Cause of Death Register; PCRR, The Psychiatric Central 
Research Register; AN, anorexia nervosa; OED, other eating disorders; MDD, major depressive disorder; OCD, 
obsessive-compulsive disorder; ASD, autism spectrum disorder; ADHD, attention-deficit/hyperactivity disorder; SUD, 
substance abuse disorder. 
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4.3 STUDY DESIGNS 
Table 4.3 Overview of the study designs and methods. 
 Study I Study II Study III Study IV 
Data 
sources 










Participants Probands born 1977-
2003 in Sweden 
(N=2,535,191) and 
1984-2006 in Denmark 
(N=1,382,367) with 







2003 with prior 
diagnoses of AN 























































Covariates Sex, birth year Sex, birth year, 
and different time 
periods (only for 
Sex, birth year, 
the first 10 
ancestry-
informative 
Sex, birth year, 
attained age, 





4.3.1 Population-based family studies 
Family studies play an important role in genetic epidemiology25. Studying multiply affected 
families is a traditional approach of gene discovery with the assumption that one or a few 
genes with strong effects on risk are carried in these families. Population-based family 
studies, on the other hand, provide the opportunity to dissect the relative contributions of 
genes and environment130. In this thesis, population-based family designs are applied to 
Studies I and II. 
Population-based family studies make it possible for valid inference to the population130. 
Familial resemblance may be due to both genetic and environmental factors. Genetic 
relatedness refers to the extent to which individuals in a family are genetically similar, 
whereas shared environmental factors comprise nongenetic factors that serve to make family 
members more similar. When the associations across relatives follow the pattern of genetic 
relatedness within families (i.e., the associations attenuate with decreasing genetic 
relatedness), the shared genetic factors are often presumed to contribute131. Figure 4.3.1 
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Abbreviations: AN, anorexia nervosa; OED, other eating disorders; EDs, eating disorders; PRS, polygenic risk scores; 




Figure 4.3.1 Genetic relatedness within a family. 
Abbreviations: MZ, monozygotic twin; DZ, dizygotic twin. 
4.3.1.1 Familial co-aggregation 
Familial co-aggregation studies explore how multiple traits cluster within families. For 
example, for two disorders such as schizophrenia and EDs, if their common risk factors are 
shared within families (genetic and/or shared environmental factors), the probability of 
suffering from schizophrenia would be higher in relatives of individuals with EDs than in 
relatives of individuals without EDs132. Therefore, an observed familial co-aggregation 
pattern may suggest familial liability for the two disorders. Alternatively, the familial co-
aggregation pattern may also be explained by a causal relationship between the disorders, 
rather than familial liability shared by the disorders (path 3, explained below). Comparing co-
aggregation of disorders across different types of relatives can implicate common familial 
liability between two disorders which provides information on the extent to which the degree 
of relatedness influences the risk of the disorders. 
The directed acyclic graph (DAG) shows a simplified potential possibility for causal 
relationships between schizophrenia and EDs132 (Figure 4.3.1.1). A more detailed explanation 
was available in Supplementary Method of Paper I. In brief, shared factors within families 
(C, including shared genetic and environmental factors) could have an effect on 
schizophrenia and ED status in probands (SCZP, EDP) and their relatives (SCZR, EDR). There 
also exist common causes for schizophrenia (USCZ) and common causes for EDs (UED). 
Confounders for schizophrenia and EDs that are not shared in families (UR, UP) are shared 
causes of schizophrenia and EDs within individuals. An association between EDP and SCZR 
(symmetric with EDR and SCZP) would suggest familial co-aggregation of schizophrenia and 
EDs. In this case, the observed association between EDP and SCZR would be explained by 
not only 1) EDP ←C→ SCZR, but also 2) EDP ←C→EDR→ SCZR, and 3) EDP ← UED 





























Figure 4.3.1.1 DAG to explain the familial co-aggregation of two disorders (schizophrenia 
and EDs as an example). 
We can adjust for EDR to block path 2) and 3). However, several additional paths would be 
open: 4) EDP ←C→EDR← UR → SCZR, 5) EDP ← UED →EDR ←C→ SCZR, and 6) EDP ← 
UED →EDR ← UR → SCZR. After adjusting for EDR, path 1), 4), 5) and 6) are open, in which 
path 6) does not contain C. However, on the other hand, if all of the arrows in the DAG stand 
for positive effects, then path 4), 5), and 6) would most likely contribute negatively to the 
association between EDP and SCZR. Therefore, if the suggested DAG is correct, when the 
observed associations remained positive after adjusting for EDR, the direct path would not be 
likely to explain all of the observed familial co-aggregation. Thus, the C—familial shared 
factors for schizophrenia and EDs, is likely to exist. 
In this thesis, familial co-aggregation methods are applied in Study I to address whether 
familial factors contribute to different types of EDs and schizophrenia. 
4.3.2 Polygenic risk score analysis 
4.3.2.1 Derivation of polygenic risk scores 
Polygenic risk scores (PRS) are continuous, normally distributed individualized indices of 
genetic risk for traits or diseases. They are generated by summing risk from multiple genetic 
loci weighted by the strength of their associations as assessed by GWAS33, 34. In brief, 
schizophrenia PRS generated in Studies III and IV followed the steps described below. We 
first performed quality control to remove duplicated and ambiguous SNPs in the overlapping 
SNPs between the individual genotype data for each study (ANGI-SE, BEGIN-SE, UK 
Biobank, respectively) and the summary statistics of the schizophrenia GWAS from the PGC. 
Next, linkage disequilibrium (LD)-clumping was performed to extract the independent loci 
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associated with schizophrenia. After that, schizophrenia PRS across different p-value 
thresholds (p < 5×10-8, p < 1×10-6, p < 1×10-4, p < 0.001, p < 0.01, p < 0.05, p < 0.1, p < 0.2, 
p < 0.5, and p < 1) were derived by aggregating SNPs with p-values below certain thresholds 
weighted by their effect sizes35 and then standardizing them. To consolidate predictive 
performance across PRS thresholds and minimize the multiple testing burden, we performed 
principal component analysis (PCA) on the set of ten PRS133. The first PC, PRS-PC1, was 
then standardized and used in Studies III and IV. 
4.3.2.2 Application of polygenic risk scores 
PRS is an individual score representing personal genetic risk of a trait/disorder derived from 
common genetic variants. It can be flexibly applied in multiple analyses. One early 
application of PRS was to detect common polygenic variation between schizophrenia and 
bipolar disorder134. Another study also applied PRS in the examination of five major 
psychiatric disorders to find common polygenic risk between them135. Schizophrenia PRS is 
also utilized to examine the impact of genetic risk on cognition in schizophrenia, 
antipsychotic efficacy, and on underlying neurobiology of schizophrenia via neuroimaging 
studies136-138. In this thesis, schizophrenia PRS were applied in Studies III and IV to 
investigate whether the spectrum of genetic risk for schizophrenia influences the clinical 
presentations of EDs, and whether schizophrenia genetic variants also confer increased risk 
for conditions commonly comorbid with schizophrenia. 
4.3.3 Phenome-wide association studies (PheWAS) 
A PheWAS is an approach to test for associations between a specific genetic variant, or a 
combination of variants (e.g., PRS), and a wide range of phenotypes in large numbers of 
individuals (Figure 4.3.3)139, 140. PheWAS have the advantage of identifying pleiotropic 
properties. In this thesis, we applied this method in Study IV to identify illnesses associated 
with schizophrenia PRS. 
 
Figure 4.3.3 Phenome‐wide association studies (PheWAS). (Reprinted from Robinson JR, 
Denny JC, Roden DM, Van Driest SL. Genome-wide and Phenome-wide Approaches to 
Understand Variable Drug Actions in Electronic Health Records. Clin Transl Sci. 2018 
Mar;11(2):112-122. doi: 10.1111/cts.12522. with permission from John Wiley and Sons)140. 
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4.4 STATISTICAL METHODS 
4.4.1 Linear regression 
Linear regression models are usually used for continuous outcomes. They estimate the 
change in outcome per one-unit change in exposure while adjusting for potential confounding 
and/or mediation by other covariates through statistical adjustment in the regression models. 
This assumes linearity between the exposure and outcome, independence of errors, normally 
distributed outcome for any exposure, constant variance for the errors in outcomes 
independent of the exposure. Assumptions of normality and constant variance can be relaxed 
using a robust sandwich estimator141.  
4.4.2 Logistic regression 
Logistic regression models are commonly used for binary outcomes to estimate the change of 
log-odds for the outcome per unit change in the exposure level while adjusting for potential 
confounding and/or mediation by other covariates through statistical adjustment in the 
regression models. The exponents of the regression coefficients are the odds ratios (ORs). For 
binary exposures, ORs can be interpreted as the odds of developing the outcome in the 
exposed group compared with the unexposed group. For continuous exposures, ORs can be 
interpreted as the change in odds of developing the outcome per unit increase in the exposure 
level.  
4.4.3 Cox regression 
Cox regression models are widely used for time-to-event outcomes in survival analyses to 
compare the hazard (event rate) of an event in the exposed group vs. unexposed group 
estimated by hazard ratios (HRs) while adjusting for potential confounding and/or mediation 
by other covariates through statistical adjustment in the regression models. It assumes that the 
hazards for different levels of exposure are proportional and the difference between two 
hazards (i.e., HR) is constant over time. Cox regression models do not make any assumption 
about the shape of the hazard function. HRs are automatically adjusted for the underlying 
time scale since the comparison is made at each time point.  
4.4.4 Time-split Poisson regression 
Poisson regression models are commonly used to model count data. The regression 
coefficient can be interpreted as the change in the logs of expected counts per one-unit 
change in the exposure while adjusting for potential confounding and/or mediation by other 
covariates through statistical adjustment in the regression models. Moreover, by splitting the 
follow-up time in each individual in Poisson regression and applying different baseline rates 
in each time window, different underlying rates over time can be adjusted in the model. In 
addition, this splitting of follow-up time can be made on a combination of time scales 




5 RESULTS  
5.1 SCHIZOPHRENIA AND EATING DISORDERS CO-AGGREGATE IN 
FAMILIES (STUDY I) 
5.1.1 Increased schizophrenia risk in individuals with eating disorders 
The overall prevalence of schizophrenia in probands in the study population was 0.12% in 
Sweden and 0.45% in Denmark. When stratified by ED subgroups, the prevalence of 
schizophrenia was higher in probands with AN (0.56% in Sweden, 3.17% in Denmark) or 
OED (0.63% in Sweden, 3.72% in Denmark) than in the general population. Individuals with 
AN or OED all had significantly increased risks of schizophrenia, and the ORs for 
schizophrenia in AN vs OED did not differ significantly in either country. Males with AN or 
OED had a significantly higher risk for schizophrenia than females in Sweden, but not in 
Denmark (Table 5.1.1). 
Table 5.1.1 Increased schizophrenia risk in EDs. 
 
5.1.2 Co-aggregation of schizophrenia and eating disorders in families 
Increased risk of schizophrenia was detected in full siblings and in half siblings of probands 
with AN compared with full siblings and half siblings of probands without AN (Figure 
5.1.2.1). For other types of relatives, there was either no association or inconsistent evidence 
  OR (95% CI) of Schizophrenia 
 Sweden Denmark 
AN    
Total proband population 5.66 (4.46, 7.19) 6.17 (5.38,7.08) 
Female 5.17 (4.00, 6.68) 6.18 (5.36,7.13) 
Male 10.99 (5.88, 20.53) 6.08 (3.68,10.06) 
OED    
Total proband population 6.15 (5.14, 7.36) 7.17 (6.41, 8.01) 
Female 5.47(4.50, 6.64) 7.22 (6.42, 8.12) 





Note: ORs with 95% CI for schizophrenia in individuals with EDs compared to individuals without EDs 
presented, stratified by sex.  
Abbreviations: OR, odds ratio; CI, confidence interval; EDs, eating disorders; AN, anorexia nervosa; OED, 




between the two countries. However, the risk of schizophrenia attenuated with decreasing 
genetic relatedness among the youngest generation (full sibling > half sibling > cousin). 
 
 
Figure 5.1.2.1 ORs for schizophrenia in individuals with AN and their relatives, compared 
with individuals without AN and their relatives142. 
Increased risk of schizophrenia was found in all relatives of probands with OED; however, 
the effects were not statistically significant among half siblings and uncles/aunts in Denmark 
(Figure 5.1.2.2). Overall, the magnitude of ORs attenuated with decreasing genetic 
relatedness. 
 
Figure 5.1.2.2 ORs for schizophrenia in individuals with OED and their relatives, compared 
with individuals without AN and their relatives142. 
A significant increase was also found in the ORs for schizophrenia in parents of probands 
with OED compared in parents of probands with AN in both countries (p<0.01).  
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5.2 ASSOCIATION BETWEEN FAMILY HISTORY OF SCHIZOPHRENIA AND 
CLINICAL OUTCOMES IN INDIVIDUALS WITH EATING DISORDERS 
(STUDY II) 
A first-degree family history of schizophrenia was present for 0.76% of individuals with AN 
and 0.96% of individuals with OED in the study population. Approximately 5% of the study 
population (individuals with AN or OED) had at least one relative (including up to third 
degree relatives) with schizophrenia. 
5.2.1 Association of family history of schizophrenia and ED clinical features 
in individuals with AN or OED 
Among individuals with AN, those with any family history of schizophrenia had significantly 
lower EDEQ-scores for all subscale and global scores compare to those without. And those 
with first-degree relatives with schizophrenia had a 1.14kg/m2 (p=0.018) higher lowest 
illness-associated BMI compared to those without. No statistically significant association was 
observed between family history of schizophrenia and ED clinical features in individuals with 
OED (Figure 5.2.1). 
Figure 5.2.1 Regression coefficients with 95% CI for ED clinical features associated with 
family history of schizophrenia in individuals with AN(a) vs. OED (b)143.  




5.2.2 Risk for psychiatric comorbidities, cumulative somatic and mental 
health burden, and suicide attempts in individuals with AN or OED 
First-degree family history of schizophrenia was associated with an increased risk for 
comorbid anxiety disorders, ADHD, and SUD in both individuals with AN and individuals 
with OED. Among individuals with OED, a first-degree family history of schizophrenia was 
also associated with elevated comorbid OCD (Figure 5.2.2.1 & Figure 5.2.2.2).  
Figure 5.2.2.1 HRs and IRRs with 95% CI for psychiatric comorbidities and cumulative 
somatic and mental health burden associated with family history of schizophrenia in 
individuals with AN143.  
Note: * indicates statistically significant at p <0.05.  
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Figure 5.2.2.2 HRs and IRRs with 95% CI for psychiatric comorbidities and cumulative 
somatic and mental health burden associated with family history of schizophrenia in 
individuals with OED143. 
Note: * indicates statistically significant at p <0.05. 
Any family history of schizophrenia was associated with increased cumulative somatic and 
mental health burden for both AN and OED (Figure 5.2.2.1 & Figure 5.2.2.2). Moreover, a 
first-degree family history of schizophrenia was also significantly associated with elevated 
suicide attempts among individuals with OED (Figure 5.2.2.2). 
5.3 POLYGENIC RISK SCORES FOR SCHIZOPHRENIA ASSOCIATED WITH 
EATING DISORDER CLINICAL PRESENTATIONS (STUDY III) 
5.3.1 Association of schizophrenia PRS and ED clinical features in ANGI-SE 
and BEGIN-SE cases 
Schizophrenia PRS was significantly negatively associated with CIA scores in ANGI-SE 
cases, but positively associated with EDE-Q scores in BEGIN-SE cases. Among BEGIN-SE 
cases, higher schizophrenia PRS was associated with earlier age at first ED symptom and 
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more ED-related hospital contacts. No statistically significant association was observed 
between lowest/highest BMI and schizophrenia PRS in either ANGI-SE or BEGIN-SE cases 
(Table 5.3.1). 
Table 5.3.1 ED clinical features and schizophrenia PRS. 








Age at first ED 
symptom 
0.01 (-0.05, 0.07) 0.708 -0.13 (-0.24, -0.02) 0.018 
Lowest BMI 0.01 (-0.03, 0.05) 0.656 -0.05 (-0.18, 0.08) 0.450 
Highest BMI - - 0.01 (-0.16, 0.19) 0.881 
CIA score -0.20 (-0.38, -0.02) 0.032 - - 
EDE-Q global 
score 
- - 0.06 (0.02, 0.11) 0.009 
EDE-Q restraint - - 0.05 (0.00, 0.10) 0.059 
EDE-Q eating 
concern 
- - 0.06 (0.01, 0.10) 0.015 
EDE-Q shape 
concern 
- - 0.07 (0.01, 0.12) 0.019 
EDE-Q weight 
concern 
- - 0.07 (0.02, 0.13) 0.007 
Total ED related 
hospital contacts 
0.00 (-0.03,0.03) 0.998 0.08 (0.02, 0.15) 0.012 
Total inpatient 
days related to 
ED 
0.03 (-0.02, 0.08) 0.249 0.04 (-0.08, 0.16) 0.481 
     Abbreviations: CI, confidence interval; ED, eating disorder; BMI, body mass index; CIA, Clinical 





5.3.2 Risk for psychiatric comorbidities associated with schizophrenia PRS 
in ANGI-SE and BEGIN-SE cases 
Higher schizophrenia PRS was significantly associated with increased risk of comorbid MDD 
in both ANGI-SE and BEGIN-SE cases. It was also significantly associated with elevated 
comorbid SUD among BEGIN-SE cases. However, all effects were relatively small (Table 
5.3.2).  
Table 5.3.2 The HRs of psychiatric comorbidities among individuals with EDs with different 
schizophrenia PRS level. 
 
ANGI-SE cases BEGIN-SE cases 
 
HR 95% CI HR 95% CI 
Anxiety disorders 1.00 [0.98, 1.03] 1.02 [0.97, 1.07] 
MDD 1.03 [1.01, 1.05] 1.06 [1.02, 1.11] 
OCD 1.04 [1.00, 1.10] 1.01 [0.88, 1.16] 
ASD 1.05 [0.99, 1.12] - - 
ADHD 1.03 [0.98, 1.08] 1.09 [0.98, 1.20] 
SUD 1.02 [0.98, 1.05] 1.12 [1.03, 1.23] 
Schizophrenia 1.04 [0.88, 1.24] - - 
 
 
    
 
5.3.3 Risk for cumulative somatic and mental health burden associated with 
schizophrenia PRS in ANGI-SE and BEGIN-SE cases 
Among BEGIN-SE cases, higher schizophrenia PRS was associated with receiving more 
diagnoses on average. However, no association was observed in cumulative health burden 
with schizophrenia PRS in ANGI-SE cases (Table 5.3.3).  
  
Abbreviations: HR, hazard ratio; CI, confidence interval; MDD, major depressive disorder; OCD, 
obsessive-compulsive disorder; ASD, autism spectrum disorder; ADHD, attention-




Table 5.3.3 IRRs of cumulative somatic and mental health burden among individuals with 
EDs with different schizophrenia PRS level. 
 
ANGI-SE cases BEGIN-SE cases 
 
IRR 95% CI IRR 95% CI 
Total diagnoses  0.99 [0.97, 1.01] 1.05 [1.00, 1.10] 
Total unique diagnoses 1.00 [0.98, 1.01] 1.01 [0.98, 1.05] 
Total inpatient days 1.01 [0.97, 1.05] 1.05 [0.98, 1.12] 
     
 
Similar trends and patterns hold after restricting analyses to AN and OED cases for all above 
outcomes (from 5.3.1 to 5.3.3) without diagnostic crossover within individuals (i.e., AN-only 
vs. OED-only subgroups). More details can be found in the supplements of Paper III. 
5.4 SCHIZOPHRENIA GENETIC RISK ASSOCIATED WITH MULTIPLE 
ILLNESSES IN INDIVIDUALS WITHOUT SCHIZOPHRENIA (STUDY IV) 
5.4.1 Association of schizophrenia PRS and general health condition 
Higher schizophrenia PRS was significantly associated with poorer general health among 
individuals without schizophrenia in terms of both poorer self-report overall health rating and 
receiving more hospital inpatient diagnoses and more unique diagnoses on average. A similar 
association was also detected for primary care diagnoses, albeit not statistically significant, 
which might be due to the incomplete coverage of the primary care information for the study 
population (63% individuals did not have available primary care information) (Table 5.4.1). 
  





Table 5.4.1 General health conditions and schizophrenia PRS-PC1.  
 Regression coefficient (95% CI) p-value 
Overall health rating (self-report), 
N=334,586 
0.02 (0.01, 0.02) 2.02´10-32 
Total diagnoses, Number of individuals 
Inpatient, N=324,511 0.12 (0.06, 0.19) 5.24´10-5 
Primary care, N=151,643 0.80 (-0.89, 2.49) 0.35 
Unique phecodes, N=324,493 0.09 (0.05, 0.13) 3.03´10-5 
   
 
5.4.2 Risk for ICD-10 main chapters associated with schizophrenia PRS 
Schizophrenia PRS was significantly associated with five ICD-10 main chapters after 
Bonferroni correction. The strongest and most significant association was with Chapter V, 
mental and behavioral disorders, followed by Chapter X, respiratory diseases, Chapter XV, 
pregnancy, childbirth and the puerperium, and Chapter XI, digestive diseases. We also found 
a significant negative association between schizophrenia PRS and Chapter XIII, diseases of 
the musculoskeletal system and connective tissue (Figure 5.4.2).  





Figure 5.4.2 ORs with 95% CI for ICD-10 main chapters associated with schizophrenia 
PRS144.  
Note: * indicates statistically significant associations after Bonferroni correction (p<0.003). Chapter 
names corresponding to chapter numbers: 1= Certain infectious and parasitic diseases; 2 = 
Neoplasms; 3 = Blood and blood-forming organs and certain disorders involving the immune 
mechanism; 4 = Endocrine, nutritional and metabolic diseases; 5 = Mental and behavioral disorders; 
6 = Nervous system disorders; 7 = Eye and adnexa disorders; 8 = Ear and mastoid process 
disorders; 9 = Circulatory system disorders; 10 = Respiratory system disorders; 11 = Digestive 
system disorders; 12 = Skin and subcutaneous tissue disorders; 13 = The musculoskeletal system and 
connective tissue disorders; 14 = The genitourinary system disorders; 15 = Pregnancy, childbirth and 
the puerperium; 17 = Congenital malformations, deformations and chromosomal abnormalities. 
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5.4.3 Risk for 603 tested phenotypes associated with schizophrenia PRS  
Thirty-one phenotypes were significantly associated with schizophrenia PRS after Bonferroni 
correction (p< 8.29 × 10−5), including 20 phenotypes located in the chapters highlighted in the 
previous step 5.4.2 (Figure 5.4.3). In addition to the five chapters mentioned above, six 
phenotypes from the Chapter IV, endocrine, nutritional and metabolic diseases, were found to 
be associated with schizophrenia PRS in opposite directions including negative associations 
in obesity, diabetes mellitus, type 2 diabetes, and positive associations in pituitary 
hyperfunction. Moreover, several single associations were detected from circulatory system 
disorders, neurological diseases and other groups.  




6 DISCUSSION  
6.1 MAIN FINDINGS AND INTERPRETATION 
Main findings from this thesis suggest that familial liability contributes to the association 
between schizophrenia and EDs. Family history of schizophrenia influences clinical 
presentations of EDs differently in individuals with AN vs. OED. Furthermore, genetic risk 
of schizophrenia conferred by common SNPs not only modifies clinical presentations of EDs, 
but also has direct effects on multiple medical conditions in individuals without 
schizophrenia. 
6.1.1 Schizophrenia and eating disorders co-aggregated in families 
Study I, prompted by observations of significant genetic correlations between schizophrenia 
and AN10, 11, 85, delved deeper into the relationship using extensive register data from two 
countries—Sweden and Denmark, representing built-in replication. Specifically, we found 
that individuals with any type of ED had 6-7 times higher odds of schizophrenia than 
individuals without any ED. All relatives of individuals with AN or OED (except parents and 
uncles/aunts of individuals with AN) were at increased risk of schizophrenia142. The 
interpretation of the association between schizophrenia and AN observed in probands and full 
siblings but not parents is not immediately obvious. One potential explanation could be the 
low fecundity in schizophrenia145, since our cohorts were established from probands to 
parents where individuals with schizophrenia who did not have children would not be 
represented. However, it might not be the only factor as we did observe association between 
OED and schizophrenia in proband-parent pairs. Shared childhood environmental factors for 
schizophrenia may also have an effect on the observed pattern, given that shared 
environmental factors contribute to 11% of the liability to schizophrenia29. In terms of the 
association between schizophrenia and OED, the magnitude of the association decreased as 
genetic relatedness decreased suggesting a common genetic contribution for schizophrenia 
and OED.  
By studying large population-based cohorts from two countries, Study I highlights the 
increased risk of schizophrenia in individuals with EDs and suggests the existence of shared 
risk factors between schizophrenia and EDs, particularly OED. Studies further distinguishing 
the specific and shared genetic factors for schizophrenia and OED including GWAS of BN 
and BED, SNP-based genetic correlation calculation, etc. will be needed to better understand 
the underlying mechanism. 
6.1.2 Family history and polygenic risk scores for schizophrenia associated 
with eating disorder clinical presentations 
As follow-up studies of Study I, Studies II and III further investigated how shared familial 
factors between schizophrenia and EDs influence the clinical presentations in EDs. In 
particular, we used family history of schizophrenia in Study II and schizophrenia PRS in 
Study III to index the familial and SNP-based genetic risks for schizophrenia respectively for 
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individuals with EDs. Different patterns of ED clinical features, psychiatric comorbidities, 
and illness burden were observed in individuals with and without a family history of 
schizophrenia or with different schizophrenia PRS levels in AN vs OED. Intriguingly, we 
found a parallel significant negative association between risk (familial and SNP-based) of 
schizophrenia and severity of ED symptoms in individuals with AN suggesting less severe 
ED pathology in people with a positive family history or schizophrenia or higher 
schizophrenia PRS143. Significantly elevated psychiatric comorbidities as well as cumulative 
health burden were associated with both family history and PRS of schizophrenia in 
individuals with OED. This observation suggests a potential cluster of individuals who may 
be particularly high on a general psychopathology factor driven by genetic predisposition that 
leads to multiple common psychopathologies146. Notably, the magnitude of the effects was 
relatively small when assessed by schizophrenia PRS than with family history of 
schizophrenia. Several explanations are possible: first, the genetic risk carried by family 
history of schizophrenia incorporates multiple types of genetic factors. CNVs, rare mutations, 
common SNPs and their interactions might all contribute to the association detected with 
family history of schizophrenia, while PRS only indexes common SNP risk147. Another 
possible explanation for this is that family history studies cannot distinguish between shared 
genetic and environmental factors, and the observed association assessed by family history of 
schizophrenia could result from a significant shared environmental component. Further 
studies would benefit from focusing on how the different types of genetic variation, 
environmental contributions and their interactions impact the clinical presentations, 
comorbidities, and treatment response in individuals with EDs to better understand the 
mechanisms underlying their clinical heterogeneity. 
6.1.3 Schizophrenia polygenic risk scores confer risk for multiple health 
conditions 
Results from Study IV extend the knowledge of pleiotropic effects of schizophrenia PRS 
observed previously36. Our findings show that individuals with a higher schizophrenia PRS 
are more likely to have poorer self-reported overall health, receive more hospital inpatient 
diagnoses, and have a more multi-morbid clinical picture, even though they had never 
received a diagnosis of schizophrenia.  
In line with previous studies of positive genetic correlations between schizophrenia and 
multiple psychiatric disorders36, 135, 148, 149, we also detected significant associations between 
schizophrenia PRS and bipolar disorder, mood disorder, SUD, and anxiety disorders. These 
findings further support the concept of general p factor146. Moreover, novel associations 
between schizophrenia PRS and several respiratory diseases including chronic bronchitis, 
chronic airway obstruction, and asthma were observed in our study. Given the elevated risk 
of respiratory diseases and high prevalence of smoking in individuals with schizophrenia150-
152, it is easy to hypothesize that the association between schizophrenia PRS and respiratory 
diseases is mediated through the effect of smoking. However, our sensitivity analysis 
suggested the existence of a direct effect from schizophrenia PRS to respiratory diseases 
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independent of smoking (Paper IV, Table S3). Furthermore, we also observed novel 
associations between schizophrenia PRS and digestive diseases which provide evidence for 
the shared genetic basis between these illnesses that have demonstrated comorbidity153-155. 
Notably, remarkable significant negative associations were observed between schizophrenia 
PRS and musculoskeletal diseases, indicating the possible involvement of immune 
mechanisms in the pathophysiology of schizophrenia30, 156. Future studies incorporating the 
genetic basis of involvement of immune mechanisms in the pathophysiology of schizophrenia 
would improve our understanding of the underlying etiology of schizophrenia. Integrating the 
effect of potential mediating factors including alcohol consumption, smoking, socioeconomic 
status, and/or other environmental factors may assist future application of schizophrenia PRS 
in clinical practice. 
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Misclassifications and measurement errors 
Studies I and II defined AN, OED, schizophrenia, and other psychiatric comorbidities from 
diagnostic records from registers, which may lead to an under-detection of the disorders for 
several reasons. First, the outpatient diagnostic records are only available after 2001 in 
Sweden. Any outpatient visit relevant to the disorder of interest before 2001 in Sweden was 
not captured. Second, it is difficult to fully capture the records of interest from private 
caregivers in both Sweden and Denmark. Third, it is also not possible to capture individuals 
with disorders of interest who did not seek healthcare from sources linked to the registers. 
Fourth, since the individuals can only be followed until the latest update of the data, it is 
impossible to capture diagnoses that commonly appear later in life for those individuals at a 
relatively young age. It will also lead to an unbalanced under-detection of different disorders 
(i.e., schizophrenia might be more under-detected than EDs in individuals born after e.g., 
1997). However, it can be ameliorated to some extent when we assess schizophrenia in 
relatives (especially the older generations) and EDs in probands. Under-detection of the 
disorders might result in an underestimation of the effects.  
Although ANGI-SE and BEGIN-SE recruited cases primarily based on their AN or OED 
diagnosis respectively, they are independent studies with different inclusion criteria and 
recruitment procedures125, 157 as described in 4.1.2 and 4.1.3. Thus, the different patterns 
observed for ANGI-SE vs BEGIN-SE in Study III might not be necessarily due to the 
differences between AN vs. OED, but rather be due to study differences including 
recruitment procedures, different exclusion criteria and/or time periods, etc. However, our 
sensitivity analyses (Paper III, Table S3-S5) took this possible source of bias into account, 
and the results suggest that the patterns still hold for diagnostic groups (AN vs. OED).  
6.2.2 Recall bias and missing data 
Several measurements from ANGI-SE and BEGIN-SE used in Study III were from self-report 
answers including age at first ED-related symptom, lowest weight, and highest weight after 
reaching adult height. Individuals might not remember their age at first ED-related symptom 
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clearly, especially for those who were mid-life at recruitment. Lowest weight and highest 
weight might also be more vulnerable to recall bias for those participants who were older.  
In Study II, a significant portion of individuals (43%-73%) were with missing information for 
BMI, GAF score, or EDE-Q scores. In Study IV, 63% individuals did not have available 
information on primary care diagnoses. Significant portions of missing data may reduce 
statistical power and render the remaining population less representative. 
6.2.3 Considerations in polygenic approach 
Studies III and IV used schizophrenia PRS as an index of schizophrenia genetic 
predisposition. However, several limitations of PRS need to be taken into consideration when 
interpreting the results: First, LD-based clumping as part of the generation of PRS might 
reduce the performance of PRS as the index SNPs were selected based on p-values within a 
certain LD range rather than their functionality. Second, PRS only captures genetic risk 
conferred by common SNPs, future studies integrating different types of genetic information 
is needed for a better understanding of the underlying mechanisms. Furthermore, the lack of 
diversity in populations involved in GWAS studies and PRS analyses limits the 
generalizability of the results to non-European populations158. 
6.3 ETHICAL CONSIDERATIONS 
6.3.1 Register Data 
Registry-based projects (Studies I-III) relying on general or health–related registers in 
Sweden and Denmark have been approved by the Regional Ethics Review Board in 
Stockholm, Sweden and the Health Data Protection Agency in Denmark. The data used for 
analyses are anonymized. “Personal number” is pseudonymized and the key is secured at the 
government agency (Statistics Sweden, the National Board of Health and Welfare, and 
Statistics Denmark, etc.) responsible for the data matching separated from the dataset used for 
statistical analysis. Researchers cannot access the key without approval from the ethics 
committees or trace back to personal information, maintaining the participants’ integrity. 
Furthermore, analyses and publication of data are aggregated on population level, and no 
individual data was presented. Therefore, the possibility of recognizing or identifying a 
specific person is largely eliminated. Moreover, efforts have been made to properly present 
and interpret the results in order to help protect vulnerable subjects. No personal level 
information was presented, and the results should not be misinterpreted. 
6.3.2 Survey and genotype Data 
Studies III and IV analyzed data from ANGI-SE, BEGIN-SE, and UK Biobank. These studies 
(ANGI-SE and BEGIN-SE) have been approved by the Regional Ethics Review Board in 
Stockholm, Sweden. The UK Biobank has already received ethical approval from the 
Research Ethics Committee and participants provided written informed consent. Study IV was 
approved by the UK Biobank committee. In ANGI-SE, BEGIN-SE, and UK Biobank, all 
participants provided informed consent prior to entering the study. The participants are 
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informed about how their information would be used to support health-related research, and 
any participant can withdraw at any time. Both genotype and phenotype data from UK 
Biobank have been de-identified before being delivered for research. Data from ANGI-SE 
and BEGIN-SE are pseudonymized, and the keys are kept by the principal investigators. 
Researchers can only access data with serial numbers for analyses. Additionally, the 
interpretation of the results must also be careful to avoid stigmatization. Genetic risk is 







In summary, this thesis enhances the understanding of the convergent etiology among 
schizophrenia, EDs, and other medical conditions; provides insights into the diverse 
manifestations of EDs by highlighting the impact of schizophrenia genetic risk on ED clinical 
presentations; and extends the knowledge of its pleiotropic effect in individuals without 
schizophrenia. In particular: 
• Familial liability contributes to the association between schizophrenia and EDs and 
the patterns are different in AN vs. OED. These patterns may be relevant for 
clinicians as they may impact case conceptualization and treatment decisisons. 
  
• Individuals with EDs with family histories of schizophrenia showed less severe ED-
related symptoms, higher risk of psychiatric comorbidities, and higher illness burden 
compared with those without a family history of schizophrenia. These findings shed 
light on a potential predictor (family history of schizophrenia) of clinical course and 
response to be tested in the future.  
 
• Genetic risk for schizophrenia predisposes individuals with EDs to elevated risk of 
psychiatric comorbidities including MDD and SUD. Higher schizophrenia PRS is 
associated with severity of EDs and age at first ED symptom in opposite directions in 
AN vs OED. These findings support the hypothesis that the genetic liability of 
schizophrenia influences clinical presentations of EDs and these patterns differ for 
AN cases vs. OED cases.  
 
• Significant associations exist between schziophrenia PRS and multiple medical 
conditions, particularly immune-related diseases. These findings corroborate the 
pleiotropic effect of schizophrenia PRS and suggest the involvement of hormone 





8 FUTURE PERSPECTIVES 
Both schizophrenia and EDs, as well as many common comorbidities, are complex traits. 
Even though this thesis provides significant evidence for several specific research questions 
related to their etiology, there are multiple ways to extend our understanding of the 
convergent etiology among schizophrenia, EDs, and other medical conditions in the future:  
1) Improve the performance of PRS by prioritizing SNPs that are most likely functional 
identified from multiple sources (e.g., eQTL, pQTL, etc.). 
2) Combine the optimized PRS with other genomic information including CNVs, rare 
mutations, whole exome sequencing to understand the genetic architecture in a whole. 
3) Increase the population diversity in genetic and epidemiological research to expand 
our understanding of the etiology in non-European and mixed-ancestry populations. 
4) Identify clinically meaningful disorder subtypes with integrative genomic and 
epidemiological data and approaches. 
In summary, given the complexities of schizophrenia, EDs, and their comorbidities, this 
thesis still just begins to dissect the relationships between them. Additional efforts should be 
made to better understand the etiology which can contribute to improving the precision of 
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